International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis

Blood

Volumn 121, Issue 13, 2013, Pages 2393-2401

  Gotlib, Jason ^a   Pardanani, Animesh ^b   Akin, Cem ^c   Reiter, Andreas ^d   George, Tracy ^a   Hermine, Olivier ^e   Kluin Nelemans, Hanneke ^f   Hartmann, Karin ^g   Sperr, Wolfgang R ^h   Brockow, Knut ⁱ   Schwartz, Lawrence B ^j   Orfao, Alberto ^k   DeAngelo, Daniel J ^l   Arock, Michel ^m   Sotlar, Karl ⁿ   Horny, Hans Peter ⁿ   Metcalfe, Dean D ^o   Escribano, Luis ^k   Verstovsek, Srdan ^p   Tefferi, Ayalew ^b   Valent, Peter ^h   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CNRS   (France)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF COLOGNE   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^k UNIVERSITY OF SALAMANCA   (Spain)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; ASCITES; CYTOPENIA; HEPATOMEGALY; HUMAN; HYPOALBUMINEMIA; LIVER DYSFUNCTION; MAST CELL LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; REVIEW; SPLENOMEGALY; SURVIVAL TIME; SYSTEMIC MASTOCYTOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; CLINICAL COMPETENCE; CLINICAL TRIAL (TOPIC); COMMUNITY CARE; CONFERENCE PAPER; CONSENSUS; CONSENSUS DEVELOPMENT; DISEASE COURSE; EUROPE; HEMATOLOGIC DISEASE; INTERNATIONAL COOPERATION; LEGAL ASPECT; MASTOCYTOSIS; MEDICAL SOCIETY; ORGAN DYSFUNCTION SCORE; ORGANIZATION AND MANAGEMENT; STANDARD;

CLINICAL COMPETENCE; CLINICAL TRIALS AS TOPIC; COMMUNITY NETWORKS; CONSENSUS; DISEASE PROGRESSION; EUROPE; HEMATOLOGIC DISEASES; HUMANS; INTERNATIONAL COOPERATION; MASTOCYTOSIS; MASTOCYTOSIS, SYSTEMIC; ORGAN DYSFUNCTION SCORES; SOCIETIES, MEDICAL;

MLCS; MLOWN;

EID: 84878423607     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-458521     Document Type: Review

References (58)

1. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res. 2001;25(7): 603-625.
2. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis. In: Swerdlow S, Campo E, Lee Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:53-63.
3. Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(4): 362-371.
4. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6): 435-453.
5. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood. 2010;116(26):5812-5817.
6. Escribano L, Diaz-Agustin B, López A, et al. Spanish Network on Mastocytosis (REMA); Proposals of the Spanish Network on Mastocytosis (REMA). Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Cytometry B Clin Cytom. 2004;58(1):1-8.
7. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25(7):529-536.
8. Böhm A, Födinger M, Wimazal F, et al. Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol. 2007;120(1):192-199.
9. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18): 3769-3772.
10. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2011;24(4):585-595.
11. Arredondo A, Jennings C, Shier L, et al. CD30 expression in mastocytosis. Mod Pathol. 2011; 24:285a.
12. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26(3):451-463.
13. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA. 1999;96(4):1609-1614.
14. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7): 2366-2372.
15. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31(8):686-692.
16. Growney JD, Clark JJ, Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106(2): 721-724.
17. Gotlib J, DeAngelo DJ, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of a fully accrued phase II trial [abstract]. Blood. 2010; 116(1):Abstract 316. [ASH Annual Meeting Abstracts]
18. Hochhaus A, Ottmann OG, Lauber S, et al. A phase II study of nilotinib, a novel inhibitor of c-KIT, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis [abstract]. Blood. 2006;108(1):Abstract 2703. [ASH Annual Meeting Abstracts]
19. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906-3915.
20. Purtill D, Cooney J, Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: Four cases. Eur J Haematol. 2008;80(5):456-458.
21. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103(8):3222-3225.
22. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE. 2009;4(9): E7258.
23. Georgin-Lavialle S, Lhermitte L, Suarez F, et al. Mast cell leukemia: Identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol. 2012;89(1):47-52.
24. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leuk Res. 2003;27(7):635-641.
25. Gotlib J, Berubé C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865-2870.
26. Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest. 2008;38(11):869-873.
27. Quintás-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol. 2007;82(12): 1124.
28. Parikh SA, Kantarjian HM, Richie MA, et al. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010;51(2):269-274.
29. Quintás-Cardama A, Amin HM, Kantarjian H, et al. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma. 2010;51(3):540-542.
30. Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, et al. Lenalidomide therapy in systemic mastocytosis. Leuk Res. 2009;33(3):e19-e22.
31. Damaj G, Bernit E, Ghez D, et al. Thalidomide in advanced mastocytosis. Br J Haematol. 2008; 141(2):249-253.
32. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 1992; 326(9):619-623.
33. Worobec AS, Kirshenbaum AS, Schwartz LB, et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma. 1996;22(5-6):501-508.
34. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol. 1998;138(3):489-495.
35. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: Results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119(4): 1090-1097.
36. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha- 2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res. 2004;28(3):249-257.
37. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2- chlorodeoxyadenosine. Am J Hematol. 2009; 84(12):790-794.
38. Tefferi A, Li CY, Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344(4):307-309.
39. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102(13):4270-4276.
40. Lortholary O, Vargaftig J, Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: A french multicenter study of 33 patients [abstract]. Blood. 2004;104(1):Abstract 661. [ASH Annual Meeting Abstracts]
41. Pardanani A, Hoffbrand AV, Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res. 2004;28(2): 127-131.
42. Böhm A, Sonneck K, Gleixner KV, et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinibresistant KIT mutation D816V. Exp Hematol. 2010;38(9):744-755.
43. Hermine O, Hirsh I, Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 44 patients [astract]. Blood. 2010;116(1): Abstract 1982. [ASH Annual Meeting Abstracts]
44. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer. 2006;107(2):345-351.
45. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009; 33(11):1481-1484.
46. Valentini CG, Rondoni M, Pogliani EM, et al. Mast cell leukemia: A report of ten cases. Ann Hematol. 2008;87(6):505-508.
47. Pardanani A, Tefferi A. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol. 2010;84(5):371-378.
48. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood. 2009; 113(23):5727-5736.
49. Travis WD, Li CY, Yam LT, et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62(5):965-972.
50. Bernd HW, Sotlar K, Lorenzen J, et al. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol. 2004; 57(3):324-328.
51. Arredondo AR, Gotlib J, Shier L, et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge. Am J Hematol. 2010; 85(8):600-606.
52. Fritsche-Polanz R, Fritz M, Huber A, et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol. 2010;4(4):335-346.
53. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816-. Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res. 2002;26(11):979-984.
54. Pullarkat V, Bedell V, Kim Y, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007;31(2): 261-265.
55. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009;33(5):735-741.
56. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-425.
57. Tefferi A, Barosi G, Mesa RA, et al. IWG for Myelofibrosis Research and Treatment (IWGMRT). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503.
58. Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.